Hodgkin Lymphoma

In order for our site to display correctly you will need a newer version of your web browser.

Currently we test and support the following browsers:

FireFox version 3.0 and above (Windows and Mac)
Safari version 5.0 and above (Windows and Mac)
Internet Explorer version 7.0 and above (Windows)

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Research

Patient Resources

Disease Information

Leukemias / Lymphomas: Hodgkin Lymphoma

Alternate Names: Hodgkin disease

Definition

Hodgkin lymphoma is a cancer characterized by progressive enlargement of affected lymph nodes and sometimes spread to the spleen, liver, bone marrow, bones, or lungs.

Incidence

Every year in the United States, 6,000 to 7,000 new cases of Hodgkin lymphoma are diagnosed (in adults and children)..
In the United States and northern Europe, Hodgkin lymphoma is rare before the age of five, with a gradual rise in incidence until adolescence and a peak in the 20s and another peak later in adulthood.

Influencing Factors

Boys are more likely than girls to develop Hodgkin lymphoma.
Siblings of patients have a slightly increased risk of developing the disease.
The virus that causes mononucleosis (Epstein-Barr virus) is believed to play a role in the development of some cases of Hodgkin lymphoma.

Survival Rates

The survival rate today for low-stage Hogkin lymphoma is greater than 90 percent.
The survival rate for advanced disease is greater than 80 percent.

Treatment Strategies

Radiation therapy works well for localized Hodgkin lymphoma, but may significantly impair the growth of bones and soft tissues in young children and increase the risk of heart disease and second cancers as patients grow older.
Chemotherapy alone or combination therapy with chemotherapy and low-dose radiation therapy is the standard treatment for young patients and those who have more advanced disease.

Current Research

Newer risk-adapted therapies are under investigation to determine if it is possible to reduce the amount of treatment (which should reduce the long-term side effects of heart and lung disease and second cancers) and still maintain cure rates. Three treatment protocols are currently available at St. Jude for patients with Hodgkin lymphoma: HOD99, HOD05 and HOD08.
The Hodgkin consortium is based at St Jude and led by Monika Metzger, MD. It includes the following institutions: Dana Farber Cancer Institute, Stanford Comprehensive Cancer Center, Massachusetts General Hospital Cancer Center and Maine Medical Center. Collaborators work together to develop improved treatment strategies for Hodkgin lymphoma patients.
Long term side effects in survivors of Hodgkin lymphoma are being investigated in the SJLIFE studies 4,5 and 16.
Laboratory-based scientists are working with physicians to better understand the role that viruses like the Epstein-Barr virus play in the development of Hodgkin lymphoma. This information will be helpful in developing new approaches to treat Hodgkin lymphoma.

The St. Jude Web site is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

Print Email This Article